Market closedNon-fractional

Zymeworks/ZYME

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Zymeworks

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Ticker

ZYME

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Middletown, United States

Employees

275

Zymeworks Metrics

BasicAdvanced
$598M
Market cap
-
P/E ratio
-$1.77
EPS
1.15
Beta
-
Dividend rate
$598M
1.15
6.922
6.609
4.81
5.764
-16.09%
-27.64%
11.843
1.36
1.42
-7.749
-88.69%
-168.34%
17.23%
-22.51%

What the Analysts think about Zymeworks

Analyst Ratings

Majority rating from 8 analysts.
Buy

Zymeworks Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-316.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$10M
-40.83%
Net income
-$32M
119.44%
Profit margin
-316.00%
270.89%

Zymeworks Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 44.83%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.76
-$0.41
-$0.20
-$0.42
-
Expected
-$0.47
-$0.47
-$0.43
-$0.29
-$0.20
Surprise
61.55%
-12.65%
-53.89%
44.83%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Zymeworks stock?

Zymeworks (ZYME) has a market cap of $598M as of July 05, 2024.

What is the P/E ratio for Zymeworks stock?

The price to earnings (P/E) ratio for Zymeworks (ZYME) stock is 0 as of July 05, 2024.

Does Zymeworks stock pay dividends?

No, Zymeworks (ZYME) stock does not pay dividends to its shareholders as of July 05, 2024.

When is the next Zymeworks dividend payment date?

Zymeworks (ZYME) stock does not pay dividends to its shareholders.

What is the beta indicator for Zymeworks?

Zymeworks (ZYME) has a beta rating of 1.15. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy or sell Zymeworks stock

Buy or sell Zymeworks stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing